LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

36.27 -1.23

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

36.17

Максимум

36.77

Ключови измерители
By Trading Economics
Приходи	-7.4M -81M
EPS	-0.5
Служители	205
EBITDA	-6.8M -79M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+41.61% upside

Дивиденти
By Dow Jones
Следващи печалби	24.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.7B 5.8B
Предишно отваряне	37.5
Предишно затваряне	36.27

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.02.2026 г., 16:32 ч. UTC

Печалби

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13.02.2026 г., 21:57 ч. UTC

Печалби

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.02.2026 г., 21:20 ч. UTC

Печалби

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13.02.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Dollar Pares Down Early Losses -- Market Talk

13.02.2026 г., 20:39 ч. UTC

Пазарно говорене

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13.02.2026 г., 20:28 ч. UTC

Пазарно говорене

Oil Settles Week Lower -- Market Talk

13.02.2026 г., 19:51 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:29 ч. UTC

Печалби

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13.02.2026 г., 18:18 ч. UTC

Придобивния, сливания и поглъщания

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13.02.2026 г., 17:52 ч. UTC

Печалби

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13.02.2026 г., 17:16 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 17:10 ч. UTC

Придобивния, сливания и поглъщания

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13.02.2026 г., 16:59 ч. UTC

Печалби

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13.02.2026 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13.02.2026 г., 16:11 ч. UTC

Печалби

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13.02.2026 г., 16:07 ч. UTC

Пазарно говорене

Hungarian Forint Could Rise Further -- Market Talk

13.02.2026 г., 15:54 ч. UTC

Печалби

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13.02.2026 г., 15:26 ч. UTC

Пазарно говорене

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13.02.2026 г., 15:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13.02.2026 г., 15:00 ч. UTC

Печалби

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13.02.2026 г., 14:50 ч. UTC

Пазарно говорене

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13.02.2026 г., 14:44 ч. UTC

Печалби

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13.02.2026 г., 14:22 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

13.02.2026 г., 14:21 ч. UTC

Пазарно говорене

Печалби

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13.02.2026 г., 14:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Move Lower -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

41.61% нагоре

12-месечна прогноза

Среден 52 USD 41.61%

Висок 67 USD

Нисък 39 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.